NeurologyLive® Friday 5 — May 9, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Expanding Myasthenia Gravis Treatment With Newly Approved Therapy Nipocalimab: Nicholas J. Silvestri, MD, FAAN

The professor of neurology at the University of Buffalo talked about the clinical promise of nipocalimab and its role in broadening treatment options for patients with myasthenia gravis, including adolescents. [WATCH TIME: 4 minutes]

2: Accounting for Hormonal Factors in Traumatic Brain Injury Care for Women: Christine Greiss, DO

The medical director for the Center for Brain injuries at Hackensack Meridian Health provided recommendations for clinicians to consider in the rehabilitation of women with TBI. [WATCH TIME: 6 minutes]

3: Eric Baron, DO, on the Approval of CT-132: A Digital Shift in Migraine Care

Baron, a neurologist and headache specialist at Cleveland Clinic, explained the significance, clinical data, and patient potential behind CT-132, the first FDA-approved digital therapeutic for migraine prevention.

4: NeuroVoices: Brian Lin, PhD, on Targeted Therapies and Biomarkers to Drive New Momentum in ALS Research

The research portfolio director at the Muscular Dystrophy Association highlighted advances in gene-targeted therapies and biomarker development as potential key drivers of progress in ALS.

5: SMA Treatment Today: How New Therapies Are Changing Care Guidelines

In episode 1, panelists explore the evolving SMA treatment landscape, highlighting updated best practices shaped by new therapies, newborn screening, and international expert consensus.